The below Parliamentary question was asked by Lord Freyberg on 2016-05-23.
To ask Her Majesty’s Government how many primary school sites in London exceeded EU limit values of NO2 due to diesel train emissions in each of the last five years.
Lord Ahmad of Wimbledon
We do not hold information on the number of primary schools sites in London exceeding NO2 limit values due to diesel train emissions.
The below Parliamentary question was asked by Lord Freyberg on 2016-09-05.
To ask Her Majesty’s Government on what date the Department of Health referred lenvatinib to NICE for a full technology appraisal.
Lord Prior of Brampton
Ministers asked the National Institute for Health and Care Excellence (NICE) to develop technology appraisal guidance on the use of lenvatinb for the treatment of thyroid cancer on 22 July 2016. NICE plans to develop guidance on lenvatinib and sorafenib through the same technology appraisal and currently expects to publish draft guidance in October 2017.
In the absence of NICE guidance, it is for commissioners to make funding decisions based on the available evidence and on the patient’s individual clinical circumstances.
The below Parliamentary question was asked by Lord Freyberg on 2016-01-13.
To ask Her Majesty’s Government what are the latest figures for the total number and percentage of incidence of cancers and total deaths excluding non-melanoma skin cancer, for (1) the top five occurring cancers, including breast, prostate, colorectal, lung, and melanoma, (2) less common cancers with an incidence ranked six to 15 by the International Classification of Diseases code, and (3) all other lower incidence cancers.
Lord Bridges of Headley
The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.
The below Parliamentary question was asked by Lord Freyberg on 2016-02-08.
To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 4 February (HL5344), when Genomic England expects to have reported back to patients from the pilot phase on (1) 100 patients, (2) 250 patients, (3) 500 patients, (4) 1000 patients, and (5) all patients.
Earl of Courtown
The existing bilateral programme fund, run by our Embassy in Pyongyang, has contributed to a number of projects aimed at improving the lives of some of the most vulnerable people in the Democratic People’s Republic of Korea (DPRK). These include helping to improve food and nutrition for people in rural areas and equipment for the physically disabled. In addition, our funding of English language projects and visits to the UK for government officials, exposes DPRK citizens to other values and cultures. We assess that many of our existing projects contain a human rights element, without strictly being defined as a human rights project. In the coming year we will continue to fund such projects where possible and will assess future human rights projects under the Magna Carta Fund for Human Rights and Democracy. The amount spent on projects categorised as containing a human rights element between 3 September 2013-8 October 2015 was £270,046.61.
The below Parliamentary question was asked by Lord Freyberg on 2016-05-23.
To ask Her Majesty’s Government what research they have carried out into levels of NO2 emissions by diesel trains in urban areas, and whether they intend to apply similar control measures for diesel trains as have been agreed for road vehicles.
Lord Ahmad of Wimbledon
The air quality plan for nitrogen dioxide we published in December 2015 sets out a comprehensive approach to improving the UK’s air quality, reducing health impacts, and fulfilling our legal obligations. The analysis undertaken for the plan took account of the emissions from rail travel as part of the assessment of emission sources.
Whilst emissions from the rail sector are relatively low, the air quality plan set out that UK is committed to reducing them even further, along with some of the steps we are taking. For example, the Government has committed to a major rail electrification programme that will see a significant number of diesel trains progressively replaced with electric equivalents.
The below Parliamentary question was asked by Lord Freyberg on 2016-09-05.
To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 25 July (HL1340), what date has been agreed by NICE for a full technology appraisal of lenvatinib.
Lord Prior of Brampton
Ministers asked the National Institute for Health and Care Excellence (NICE) to develop technology appraisal guidance on the use of lenvatinb for the treatment of thyroid cancer on 22 July 2016. NICE plans to develop guidance on lenvatinib and sorafenib through the same technology appraisal and currently expects to publish draft guidance in October 2017.
In the absence of NICE guidance, it is for commissioners to make funding decisions based on the available evidence and on the patient’s individual clinical circumstances.
The below Parliamentary question was asked by Lord Freyberg on 2016-01-13.
To ask Her Majesty’s Government what information (1) the National Cancer Intelligence Network, (2) Public Health England, (3) the National Institute for Health Research, and (4) the NHS more broadly, hold on mesothelioma and other less common cancers covering (a) hospital surgical volumes; (b) hospital systemic anti-cancer treatment volumes; (c) hospital radiotherapy volumes; (d) clinical trial volumes by hospital; (e) cancer stage and grade at presentation; (f) short-term patient outcomes; (g) one-year survival rates; and (h) five-year survival rates.
Lord Prior of Brampton
The National Cancer Registration Service and National Cancer Intelligence Network are both part of Public Health England and collect data on all diagnoses of cancer in England, including mesothelioma and other rare cancers.
Data on one-year survival from mesothelioma have been published and is attached. The relative survival for men at one year was 34%; varying between 27% and 39% across England. The relative survival for women at one year was 40%; varying between 24% and 70% across England.
Data on hospital surgical volumes; hospital systemic anti-cancer treatment volumes; hospital radiotherapy volumes; clinical trial volumes by hospital; cancer stage and grade at presentation; short-term patient outcomes; and five-year survival rates are not held in the format requested.
Data on whether patients have been offered/entered into a clinical trial is now mandated as part of the Cancer Outcomes and Services Dataset, so we anticipate being able to report on this in the future.
Within the current financial year, the National Institute for Health Research (NIHR) Clinical Research Network has recruited up to 80 trials in less common cancers in a total of 124 recruitment sites. Details of the trials recruiting at each site are in the attached table, Trials in less common cancers in portfolio of NIHR Clinical Research Network. The NIHR does not collect information on hospital surgical volumes; hospital systemic anti-cancer treatment volumes; hospital radiotherapy volumes; cancer stage and grade at presentation; short-term patient outcomes; one-year survival rates; and five-year survival rates.
With regard to National Health Service more broadly, NHS England has advised that it does not hold the information requested.
The below Parliamentary question was asked by Lord Freyberg on 2016-02-08.
To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 4 February (HL5345), how many of the 20 patients with reports issued so far by the Genomic England cancer project had (1) a clinically actionable mutation for which the NHS will reimburse the costs of the treatment drug, and (2) a clinically actionable mutation for any trial currently open in the UK; and of those patients in both categories, how many had a clinically actionable mutation in open reading frames that would be covered by a simple next-generation sequencing panel test.
Lord O’Neill of Gatley
In 2006 the United Nations imposed restrictions on a range of goods from entering or leaving North Korea and imposed a travel ban and asset freeze against those persons designated as persons who engage in or provide support for North Korea’s nuclear-related, other weapons of mass destruction related and ballistic missile-related programmes. These restrictions were implemented in the EU in 2007, and have subsequently been expanded by the EU.
Under the current EU Regulation, UK financial institutions are able to establish banking relationships with North Korean banking institutions if there are no reasonable grounds to believe this will contribute to North Korea’s nuclear-related, other weapons of mass destruction related or ballistic missile-related programmes. In practice, there are almost no financial links between the UK and North Korea. North Korea is almost wholly dependent on China for international assistance.
The below Parliamentary question was asked by Lord Freyberg on 2016-06-13.
To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 4 February (HL5344), how many of the 1,286 genomes processed by 4 February came from (1) the rare disease programmes, and (2) elsewhere in the cancer programme; and how many of those genomes from (1) the rare disease programmes and (2) the cancer programme have now been interpreted clinically, either by GEL or the General Medical Council.
Lord Prior of Brampton
Genomics England (GeL) has confirmed that all 1,286 of the genomes quoted in my Written Answer of 4 February related to the cancer programme. GeL has also confirmed that at that time 5,102 rare disease genomes had been sequenced.
GeL is in the process of developing rare disease and cancer reports and is discussing these with clinical sites. Significant work has gone into building a pipeline to process genomic and clinical data at scale. This requires collection of complete datasets and a complex design process to minimise manual interaction with the process to improve accuracy.
The work on the pipeline is not planned to have been completed and thoroughly tested until later this year, but early results are already flowing through it and GeL has returned 39 reports to pilot sites. This number will increase steadily over the coming year as experience is gained.
The below Parliamentary question was asked by Lord Freyberg on 2016-09-05.
To ask Her Majesty’s Government when they expect lenvatinib to be available on the NHS for patients with radioiodine refractory differentiated thyroid cancer.
Lord Prior of Brampton
Ministers asked the National Institute for Health and Care Excellence (NICE) to develop technology appraisal guidance on the use of lenvatinb for the treatment of thyroid cancer on 22 July 2016. NICE plans to develop guidance on lenvatinib and sorafenib through the same technology appraisal and currently expects to publish draft guidance in October 2017.
In the absence of NICE guidance, it is for commissioners to make funding decisions based on the available evidence and on the patient’s individual clinical circumstances.